The Conversation (0)
ANGLE plc announced positive data from US and European ovarian cancer studies in 400 patients.
ANGLE plc (OTCQX:ANPCY) announced positive data from US and European ovarian cancer studies in 400 patients.
As quoted in the press release:
Evaluation of data from both ANGLE’s European study (ANG-001) led by Dr Robert Zeillinger at the Medical University of Vienna and ANGLE’s US study (ANG-003) led by Dr Richard Moore at the University of Rochester Medical Center, Wilmot Cancer Institute (New York State) shows that a test using the Parsortix system can differentiate between women with a malignant pelvic mass and those with benign tumours with a high degree of sensitivity (correctly identifying cancer) of up to 95% whilst at the same time achieving a higher specificity (low false positive rate) than existing tests.
The Parsortix test combines both high sensitivity and high specificity. Compared to CA125 for the ANG-003 samples, at a high sensitivity the Parsortix result had nearly double the specificity of the CA125 result.
These study results infer that best performance can be achieved when combining selected gene information analysed from the Parsortix harvest in an algorithm with certain patient condition information. The algorithm, which is proprietary, will be further optimised to give the best performance in the upcoming validation study. It is expected that it will be possible to apply for patent protection on the details of the algorithm strengthening ANGLE’s competitive positive further. Therefore, full details of the analyses are being restricted until this process is complete. The cancer centres involved will then publish the full results of the studies in leading peer-reviewed publications.